In the BioHarmony Drug Report Database

"Preview" Icon

Sirolimus

Rapamune (sirolimus) is a small molecule pharmaceutical. Sirolimus was first approved as Rapamune on 1999-09-15. It has been approved in Europe to treat graft rejection and kidney transplantation. It is known to target peptidyl-prolyl cis-trans isomerase FKBP1A and peptidyl-prolyl cis-trans isomerase FKBP35.

 

Trade Name

 

Rapamune
 

Common Name

 

sirolimus
 

ChEMBL ID

 

CHEMBL413
 

Indication

 

graft rejection, kidney transplantation
 

Drug Class

 

Immunosuppressives: immunosuppressant, rapamycin derivatives

Image (chem structure or protein)

Sirolimus structure rendering